The chemical class of "Crk I/II Inhibitors" comprises a diverse range of compounds that indirectly influence the functionality of Crk I/II, adapter proteins involved in multiple signaling pathways. These inhibitors operate through various mechanisms, primarily targeting upstream kinases or related signaling pathways, thereby modulating the activity of Crk I/II. Key to this class are tyrosine kinase inhibitors like Dasatinib, Erlotinib, Sorafenib, Imatinib, Gefitinib, Bosutinib, and AZD0530. These compounds inhibit key kinases such as Src family kinases, EGFR, RAF kinase, BCR-ABL, and Abl kinases. By inhibiting these kinases, the compounds can reduce Crk I/II-mediated signaling involved in crucial cellular processes like proliferation, migration, angiogenesis, and cell survival. The inhibition of these upstream kinases leads to a downstream effect on Crk I/II signaling, thereby reducing their roles in oncogenic processes and other cellular functions.
In addition to kinase inhibitors, compounds like Rapamycin, LY294002, SP600125, and Palbociclib play significant roles in modulating various cellular signaling pathways. Rapamycin, as an mTOR inhibitor, impacts pathways involved in cell growth and proliferation, indirectly influencing Crk I/II activity. LY294002, a PI3K inhibitor, and SP600125, a JNK inhibitor, can modulate signaling pathways related to cell survival, stress response, and apoptosis, which are linked to Crk I/II functions. Palbociclib, a CDK4/6 inhibitor, affects cell cycle regulation, influencing Crk I/II activity in these pathways. Overall, the "Crk I/II Inhibitors" class represents a range of chemical compounds that, through their impact on various signaling kinases and pathways, can indirectly inhibit the activity of Crk I/II. While these compounds do not interact directly with Crk I/II, their role in modulating key signaling pathways such as EGFR, PI3K/Akt, Src family kinases, and mTOR contributes to the inhibition of Crk I/II's functionality in cell proliferation, migration, and other critical cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor, Dasatinib can inhibit Src family kinases, potentially reducing Crk I/II-mediated signaling involved in cell proliferation and migration. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
An EGFR inhibitor, Erlotinib may indirectly inhibit Crk I/II signaling by reducing EGFR-mediated activation pathways, which are linked to Crk I/II functions. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A RAF kinase inhibitor, Sorafenib can potentially inhibit downstream signaling pathways involving Crk I/II, particularly in cell growth and angiogenesis. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targeting BCR-ABL and other tyrosine kinases, Imatinib can indirectly inhibit Crk I/II signaling in cancer proliferation and migration pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin may reduce Crk I/II activity indirectly by modulating downstream signaling pathways involved in cell growth and proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Another EGFR inhibitor, Gefitinib might inhibit Crk I/II signaling indirectly by affecting EGFR-dependent pathways linked to cellular migration and proliferation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor, PP2 can reduce Crk I/II-mediated signaling, particularly in pathways involving cell adhesion and migration. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY294002 might indirectly inhibit Crk I/II activity by modulating PI3K/Akt signaling pathways associated with cell survival and growth. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 can potentially reduce Crk I/II-mediated signaling in stress response and apoptotic pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor, PD 0332991 may indirectly inhibit Crk I/II activity by influencing cell cycle regulation pathways. | ||||||